Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 22, 2020 08:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Provides Regulatory Update

NEW YORK, May 22, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
May 11, 2020 07:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals Reports First Quarter 2020 Financial Results, and Provides Business Update

Worldwide Ocaliva net sales of $72.7 million in the first quarter 2020, representing 40% growth over the prior year quarter Regulatory and commercial preparations on track for tentatively scheduled...
May 06, 2020 08:30 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept to Present at the Bank of America Merrill Lynch Virtual Global Healthcare Conference

NEW YORK, May 06, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
April 27, 2020 08:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept to Announce First Quarter 2020 Financial Results on May 11, 2020

NEW YORK, April 27, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to...
March 26, 2020 08:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals Provides Regulatory and Business Update

NEW YORK, March 26, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to...
February 28, 2020 08:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept to Present at the Cowen 40th Annual Health Care Conference

NEW YORK, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
February 25, 2020 07:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results, Issues 2020 Operating Expense Guidance and Provides Business Update

Worldwide Ocaliva net sales of $249.6 million for the full year 2019, representing 40% growth over the prior year Our NDA was the first accepted by the FDA for liver fibrosis due to NASH Completed...
February 18, 2020 08:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept to Announce Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020

NEW YORK, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
January 29, 2020 08:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Completes Enrollment of Phase 3 REVERSE Study Evaluating Obeticholic Acid for the Treatment of Compensated Cirrhosis due to NASH

NEW YORK, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
January 08, 2020 08:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept to Present at the 38th Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...